Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Ultragenyx Pharmaceutical Inc. (RARE) had Return on Tangible Equity of 86.66% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$159.93M |
|
$-180.41M |
|
$27.99M |
|
$131.94M |
|
$330.82M |
|
$-170.89M |
|
$-8.65M |
|
$-179.54M |
|
$-179.54M |
|
$-180.41M |
|
$-180.41M |
|
$-180.41M |
|
$-180.41M |
|
$-170.89M |
|
$-162.99M |
|
99.77M |
|
99.77M |
|
$-1.81 |
|
$-1.81 |
|
| Balance Sheet Financials | |
$643.21M |
|
$249.96M |
|
$547.24M |
|
$1.19B |
|
$340.02M |
|
-- |
|
$841.26M |
|
$1.18B |
|
$9.16M |
|
$-208.19M |
|
$9.16M |
|
96.44M |
|
| Cash Flow Statement Financials | |
$-366.17M |
|
$308.25M |
|
$83.81M |
|
$184.16M |
|
$214.70M |
|
$30.54M |
|
$115.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.89 |
|
-- |
|
-- |
|
-- |
|
-- |
|
82.50% |
|
-106.85% |
|
-106.85% |
|
-- |
|
-112.26% |
|
-112.81% |
|
$-371.23M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.54 |
|
1.42 |
|
63.33 |
|
-1969.82% |
|
|
Return on Tangible Equity |
86.66% |
-15.16% |
|
-1969.79% |
|
$0.10 |
|
$-3.72 |
|
$-3.67 |
|